|
MSF Field Research >
1 Published Research and Commentary >
Leishmaniasis/Kala Azar >
High mortality among older patients treated with pentavalent antimonials for visceral leishmaniasis in East Africa and rationale for switch to liposomal amphotericin B
Please use
this identifier to cite or link
to this item:
http://hdl.handle.net/10144/120107
 Del.icio.us
 LinkedIn
 Citeulike
 Connotea
 Facebook
 Stumble it!
| Download this article: |
| View/Open |
File |
Description |
Size |
Format |
View/Open | 101115_Chappuis_VL-45yo-high-mort-SSG_AAC-2010_LETTER_in-press.pdf | Main article | 236Kb | Adobe PDF |
|
| Title: | High mortality among older patients treated with pentavalent antimonials for visceral leishmaniasis in East Africa and rationale for switch to liposomal amphotericin B |
| Authors: | Chappuis, François
Alirol, Emilie
Worku, Dagemlidet T
Mueller, Yolanda
Ritmeijer, Koert |
| Affiliation: | Médecins Sans Frontières, Geneva, Switzerland; Médecins Sans Frontières, Amsterdam, The Netherlands |
| Citation: | Antimicrob Agents Chemother, published online ahead of print on 15 November 2010 |
| Journal: | Antimicrobial Agents and Chemotherapy |
| Issue Date: | 15-Nov-2010 |
| URI: | http://hdl.handle.net/10144/120107 |
| DOI: | 10.1128/AAC.01298-10 |
| PubMed ID: | 21078947 |
| Additional Links: | http://aac.asm.org/cgi/content/abstract/AAC.01298-10v1 |
| Abstract: | Visceral leishmaniasis (VL; kala azar), a fatal disease if left untreated, is one of the most neglected tropical diseases.... |
| Type: | Article |
| Language: | en |
| MeSH: | Kala Azar
Visceral Leishmaniasis
Black Fever
Eastern Africa
Sudan
Uganda
Ethiopia
Antimony
Antimony Sodium Gluconate
Sodium Stibogluconate
Liposomal Amphotericin B
AmBisome
Adult
Middle Aged
Mortality |
| ISSN: | 1098-6596 |
| Rights: | Published by American Society for Microbiology
Archived on this site with permission and copyright by the American Society for Microbiology |
| Appears in topics: | Leishmaniasis/Kala Azar
|
| Related articles on PubMed | | |  | Liposomal amphotericin B for the treatment of visceral leishmaniasis.Bern C, Adler-Moore J, Berenguer J, Boelaert M, den Boer M, Davidson RN, Figueras C, Gradoni L, Kafetzis DA, Ritmeijer K, Rosenthal E, Royce C, Russo R, Sundar S, Alvar J 2006 Oct 1 |
| | | | See all 106 articles |
All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.
|
